FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Laininger Dieter</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol  QUAKER CHEMICAL CORP [ KWR ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify					
_	QUAKER CHEMICAL CORPORATION						3. Date of Earliest Transaction (Month/Day/Year) 12/15/2016								below) below)  VP & MD - SA & Primary Metals				
ONE QUAKER PARK, 901 E. HECTOR STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CONSHOHOCKEN PA 19428-2380				380										X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)											1 0130					
		Tab	le I - Noi	n-Deriv	ative	Se	curit	ies Ad	cquired,	Dis	posed c	of, or Be	neficia	ally Owne	d				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		ar)   i	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					Benefic Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common	Common Stock			12/15	5/2016				M		710	A	\$58	.26 13,	13,107(1)		D		
Common Stock			12/15	5/2016				M		1,473	3 A	\$73	.47 14	7 14,580		D			
Common Stock 12/1			12/15	5/2016	/2016					745	A	\$87	'.3 15	15,325		D			
		T							uired, D s, option					y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	4. Transaction Code (Instr. 8)		5. Number 6		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title ar Amount of Securities Underlyin Derivative (Instr. 3 a	of S Ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Following Reported Transactio (Instr. 4)	Ow For Or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$58.26	12/15/2016			М			710	(2)	0	3/05/2020	Common Stock	710	\$0.00	0		D		
Employee Stock Option (right to buy)	\$73.47	12/15/2016			M			1,473	(3)	0	2/27/2021	Common Stock	1,473	\$0.00	736		D		
Employee Stock Option (right to	\$87.3	12/15/2016			M			745	(4)	0	2/25/2022	Common Stock	745	\$0.00	1,488		D		

## **Explanation of Responses:**

- 1. Includes 46 shares acquired in Company's Dividend Reinvestment Plan between January 31, 2016 and October 31, 2016.
- 2. The options under this grant vested in three annual installments: 710 shares on March 5, 2014; 710 shares on March 5, 2015; and 710 shares on March 5, 2016.
- 3. The options for this grant vest in three annual installments: 737 shares on February 27, 2015; 736 shares on February 27, 2016; and 736 shares on February 27, 2017.
- 4. The options for this grant vest in three annual installments: 745 shares on February 25, 2016; 744 shares on February 25, 2017; and 744 shares on February 25, 2018.

## Remarks:

buy)

<u>Victoria K. Gehris, Attorney-in-Fact for Dieter Laininger</u>

12/19/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all persons by these presents, that the undersigned hereby constitutes and appoints each of Victoria K. Gehris, Stephanie M. Sykes and Robert T. Traub, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission ("SEC") a Form ID, including any amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Quaker Chemical Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of September, 2016.
/s/ Dieter Laininger
Signature

Dieter Laininger Print Name